Cargando…

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia

Chronic myelomonocytic leukaemia is a rare disease and data on the treatment are often extrapolated from myelodysplastic syndrome studies. Although several scores exist for the prognosis of overall survival in chronic myelomonocytic leukaemia, so far there is no designated score for the prediction o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huemer, Florian, Weiss, Lukas, Faber, Viktoria, Neureiter, Daniel, Egle, Alexander, Geissler, Klaus, Voskova, Daniela, Zebisch, Armin, Burgstaller, Sonja, Pichler, Angelika, Stauder, Reinhard, Sperr, Wolfgang, Lang, Alois, Pfeilstöcker, Michael, Machherndl-Spandl, Sigrid, Stampfl, Margarete, Greil, Richard, Pleyer, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816094/ https://www.ncbi.nlm.nih.gov/pubmed/29383443 http://dx.doi.org/10.1007/s00508-018-1315-2

Ejemplares similares

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
por: Pleyer, Lisa, et al.
Publicado: (2016)

Multistep pathogenesis of chronic myelomonocytic leukemia in patients
por: Geissler, Klaus, et al.
Publicado: (2022)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia
por: Geissler, Klaus, et al.
Publicado: (2020)

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
por: Pleyer, Lisa, et al.
Publicado: (2017)

Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia
por: Machherndl‐Spandl, Sigrid, et al.
Publicado: (2021)

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group
por: Leisch, Michael, et al.
Publicado: (2022)

Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype
por: Heibl, Sonja, et al.
Publicado: (2020)

Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients
por: Geissler, Klaus, et al.
Publicado: (2020)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research
por: Geissler, Klaus, et al.
Publicado: (2019)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival
por: Geissler, Klaus, et al.
Publicado: (2021)

Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia
por: Zack, Marie-Therese, et al.
Publicado: (2022)

TOP-PIC: a new tool to optimize pharmacotherapy and reduce polypharmacy in patients with incurable cancer
por: Strassl, Irene, et al.
Publicado: (2023)

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia: A case report
por: Huemer, Florian, et al.
Publicado: (2016)

Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia
por: Lackner, David, et al.
Publicado: (2022)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

Hospital outbreak caused by linezolid resistant Enterococcus faecium in Upper Austria
por: Kerschner, Heidrun, et al.
Publicado: (2019)

Significance of reduced renal function in patients with chronic myelomonocytic leukemia
por: Heschl, Julia, et al.
Publicado: (2022)

Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia
por: Weinfurtner, Christoph, et al.
Publicado: (2022)

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2021)

Significance of C-reactive protein in patients with chronic myelomonocytic leukemia
por: Liang-Fonseca, Jian, et al.
Publicado: (2022)

Evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients
por: Berning, Lucia, et al.
Publicado: (2014)

Bilaterale orbitale Affektion bei multiplem Myelom
por: Khalil, Baran, et al.
Publicado: (2023)

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
por: Valent, Peter, et al.
Publicado: (2019)

Genotypic and phenotypic evolution in a patient with chronic myelomonocytic leukemia
por: Geissler, Klaus, et al.
Publicado: (2019)

Is Myelodysplasia a Consequence of Normal Aging?
por: Heibl, Sonja, et al.
Publicado: (2021)

Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches
por: Geissler, Klaus
Publicado: (2021)

Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients
por: Schlick, Konstantin, et al.
Publicado: (2021)

C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients
por: Schlick, Konstantin, et al.
Publicado: (2019)

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis
por: Caraffini, Veronica, et al.
Publicado: (2020)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations
por: Greil, Richard, et al.
Publicado: (2018)

A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting: R-EFECT study
por: Petzer, Andreas L., et al.
Publicado: (2020)

Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).
por: Stark, A. N., et al.
Publicado: (1987)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence
por: Magnes, T., et al.
Publicado: (2021)

Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia
por: Reiser, Julia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3eeubhsm34kqcsdft8subfqf1p